http://www.100md.com
中国医学科学院肿瘤医院 内科 石远凯
【摘要】 贫血是肿瘤患者最常见的合并症之一，但是却远远没有引起医生和患者对其应有的认识。贫血对肿瘤患者生活质量产生的影响是负面的，贫血还可以加重肿瘤细胞乏氧，引起肿瘤细胞发生基因水平的改变，诱导侵袭性表型的产生，导致肿瘤细胞耐药和肿瘤进展。已经有多项临床研究证明，重组人促红细胞生成素( recombinant human erythropoeitins ， rhEPO )可以有效的提高伴有贫血的肿瘤患者的血红蛋白水平，减少患者的输血风险，有效的纠正患者的疲劳状态，改善肿瘤患者的生活质量。尽早开始抗贫血治疗，改善患者对治疗的依从性，去除影响 rhEPO 疗效的因素，可以进一步提高 rhEPO 对肿瘤患者贫血的治疗效果。
【关键词】 贫血 ; 肿瘤 ; 促红细胞生成素 ; 治疗
【 Abstract 】 Anemia is a common problem among patients with malignant disease. However, it is often under- recognized by both patients and doctors. Anemia has negative impact on cancer patients' quality of life. Furthermore, it may also contribute to tumor resistance and progression by aggravating tumor cell hypoxia, which induces genome changes and aggressive phenotype selection. Many studies have proved that recombinant human erythropoeitins (rhEPO) can increase hemoglobin rapidly, decrease the risk of emergency transfusion need and effectively treat fatigue and improve quality of life. And early intervention, improving patients' compliance and dealing with factors compromising rhEPO efficacy can optimize response to rhEPO.
【摘要】 贫血是肿瘤患者最常见的合并症之一，但是却远远没有引起医生和患者对其应有的认识。贫血对肿瘤患者生活质量产生的影响是负面的，贫血还可以加重肿瘤细胞乏氧，引起肿瘤细胞发生基因水平的改变，诱导侵袭性表型的产生，导致肿瘤细胞耐药和肿瘤进展。已经有多项临床研究证明，重组人促红细胞生成素( recombinant human erythropoeitins ， rhEPO )可以有效的提高伴有贫血的肿瘤患者的血红蛋白水平，减少患者的输血风险，有效的纠正患者的疲劳状态，改善肿瘤患者的生活质量。尽早开始抗贫血治疗，改善患者对治疗的依从性，去除影响 rhEPO 疗效的因素，可以进一步提高 rhEPO 对肿瘤患者贫血的治疗效果。
【关键词】 贫血 ; 肿瘤 ; 促红细胞生成素 ; 治疗
【 Abstract 】 Anemia is a common problem among patients with malignant disease. However, it is often under- recognized by both patients and doctors. Anemia has negative impact on cancer patients' quality of life. Furthermore, it may also contribute to tumor resistance and progression by aggravating tumor cell hypoxia, which induces genome changes and aggressive phenotype selection. Many studies have proved that recombinant human erythropoeitins (rhEPO) can increase hemoglobin rapidly, decrease the risk of emergency transfusion need and effectively treat fatigue and improve quality of life. And early intervention, improving patients' compliance and dealing with factors compromising rhEPO efficacy can optimize response to rhEPO.